ESLA
HealthcareEstrella Immunopharma, Inc.
$1.33
$-0.06 (-4.32%)
Jan 5, 2026
Price History (1Y)
Analysis
Estrella Immunopharma, Inc. is a biotechnology company in the healthcare sector. Its market capitalization stands at $50.23M. The company's financial health indicates minimal profitability, with gross margin, operating margin, and profit margin all at 0.0%. The current ratio of 0.15 suggests that Estrella Immunopharma may be facing liquidity issues. The company has a significant amount of debt, totaling $4,000, while its cash balance is $1.63M. Estrella Immunopharma's valuation context is characterized by a price-to-book ratio of -5.12 and beta of 0.56.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About Estrella Immunopharma, Inc.
Estrella Immunopharma, Inc., a clinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidate is EB103, which is in clinical trial, for the treatment of diffuse large B-cell lymphoma; EB104, which is in pre-clinical trial, to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia; and EB201, which is in pre-clinical trial, for the treatment of systemic lupus erythematosus. It has a collaborative agreement with Eureka and Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103. Estrella Immunopharma, Inc. was founded in 2006 and is headquartered in EmeryVille, California. Estrella Immunopharma, Inc. is a subsidiary of Eureka Therapeutics, Inc.
Visit website →Key Statistics
- Market Cap
- $50.23M
- P/E Ratio
- N/A
- 52-Week High
- $3.15
- 52-Week Low
- $0.73
- Avg Volume
- 282.36K
- Beta
- 0.56
Company Info
- Industry
- Biotechnology
- Exchange
- NCM
- Country
- United States